Anacor Pharmaceuticals, Inc.
) recently announced positive preliminary results on tavaborole
(AN2690) from Study 302. Tavaborole is being developed for the
prevention of onychomycosis.
Study 302 is the second of two phase III clinical trials on
tavaborole for onychomycosis. The study was conducted under the
US Food and Drug Administration's (FDA) Special Protocol
Assessment (SPA) program.
The study met both the primary and secondary endpoints. The
primary endpoint included the achievement of "complete cure"
(9.1% of patients in the tavaborole arm compared to 1.5% in the
Secondary endpoints included the achievement of a "completely
clear" or "almost clear" nail (27.5% of patients in the
tavaborole arm compared to 14.6% in the vehicle-treated arm),
achievement of mycological cure (35.9% of patients in the
tavaborole arm compared to 12.2% in the vehicle-treated arm) and
the achievement of "completely clear" or "almost clear" nail with
mycological cure (17.9% of patients in the tavaborole arm
compared to 3.9% in the vehicle-treated arm).
Anacor will file a new drug application in the US in
We are encouraged by the positive results from the second
phase III study of Anacor's tavaborole. However, we remain
concerned about the much more favorable results of
), onychomycosis candidate, efinaconazole.
Anacor carries a Zacks Rank #3 (Hold). Currently, companies
Lannett Company, Inc.
) look more attractive with a Zacks Rank #1 (Strong Buy).
ANACOR PHARMACT (ANAC): Free Stock Analysis
LANNETT INC (LCI): Free Stock Analysis Report
QLT INC (QLTI): Free Stock Analysis Report
VALEANT PHARMA (VRX): Free Stock Analysis
To read this article on Zacks.com click here.